The Tridex Protein Analyzer from IDEX offers the ability to directly measure protein titer from a bioreactor in real time.
Image courtesy of IDEX
The Tridex Protein Analyzer from IDEX Health & Science offers the ability to directly measure protein titer from a bioreactor in real time. The analyzer is a compact and an easy-to-use solution for at-line titer monitoring in a bioprocess environment. It is built to ensure that at-line results directly correlate to offline high-performance liquid chromatography methodology.
The biopharma industry has long been seeking an alternative to time-consuming offline methods currently in use, and the measurement of antibody titer is a critical parameter for manufacturing biologics and biosimilars, the company reports. The Tridex Analyzer quickly delivers accurate titer measurements over a dynamic range of 0.1–10 g/L, with minimal sample manipulation for use in R&D and process development.
The Tridex Analyzer is the first protein analyzer on the market built specifically for bioprocess monitoring, according to the company. It uses a unique trap and elute technique to accurately monitor the titer in a bioreactor. It does not require chromatography expertise, specialized training, or extensive method development. The sample flowpath is completely enclosed, lending itself to the requirements of single-use bioprocessing.
The Tridex system also offers the option to connect to an automated sampling system for complete integration into a bioprocessing environment and to deliver actionable results with just a few clicks. IDEX launched the new analyzer in July 2019.
Source: IDEX Health & Science
Clinical Supply Planning in Europe - Balancing Cost, Flexibility and Time
December 19th 2024The packaging and distribution of clinical supplies is a fundamental piece to the overall success of a clinical trial, and advance preparation can help establish a more efficient supply chain. Selecting the best geographical location for those activities, however, depends on the clinical trial protocol, business decisions, and even the investigational medicinal product (IMP) being studied.